BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-6209 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-6209\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06974929-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-6209: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:HRS-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in
  Patients With Breast Cancer\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/hrs-6209#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05781048-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HRS-6209: Phase 1 readout est. (NCT05781048)
DESCRIPTION:HRS-6209\, phase 1.\nStudy: A Phase I Clinical Study of the Saf
 ety， Tolerability，Pharmacokinetics\, and Initial Efficacy of HRS-6209 
 Monotherapy in Patients With Advanced Solid Tumors\nEstimated primary comp
 letion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/hrs-6209#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05781048
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358377-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:HRS-6209: Phase 1 readout est. (NCT07358377)
DESCRIPTION:HRS-6209\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Trial of HRS-6209-205 to Evaluate the Safety\, Tolerability\, Pharmaco
 kinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With 
 HR-Positive/HER2-Negative Cancer\nEstimated primary completion: 10 April 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-6209#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07358377
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-6209: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:HRS-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in B
 reast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-6209#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-6209: Phase 2 readout est. (NCT05582499)
DESCRIPTION:HRS-6209\, phase 2.\nStudy: Fudan University Shanghai Cancer Ce
 nter Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/hrs-6209#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-6209: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:HRS-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, or
  Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresectab
 le or Metastatic Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-6209#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894328-9181@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:HRS-6209: Phase 3 readout est. (NCT07894328)
DESCRIPTION:HRS-6209\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Ther
 apy in Patients With Advanced or Metastatic Breast Cancer\nEstimated prima
 ry completion: 30 July 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hrs-6209#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07894328
URL:https://assetmemo.bio/drug/hrs-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
